- Olympia Women's Health
- United States of America
We and selected partners, use cookies or similar technologies as specified in the cookie policy and privacy policy.
You can consent to the use of such technologies by closing this notice.
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used to help us achieve the features and activities described below. To learn more about how these trackers help us and how they work, refer to the cookie policy. You may review and change your preferences at any time.
These trackers are used for activities that are strictly necessary to operate or deliver the service you requested from us and, therefore, do not require you to consent.
These trackers help us to deliver personalized marketing content and to operate, serve and track ads.
These trackers help us to deliver personalized marketing content to you based on your behaviour and to operate, serve and track social advertising.
These trackers help us to measure traffic and analyze your behaviour with the goal of improving our service.
These trackers help us to provide a personalized user experience by improving the quality of your preference management options, and by enabling the interaction with external networks and platforms.
Your Fertility and Sterility Dialog login information is not the same as your ASRM or EES credentials. Users must create a separate account to comment or interact on the Dialog.
Register
Recent Comments
An inexpensive, internet-based, electronic health record (EHR) for use by all fertility clinics could accumulate big data on treatments used and outcomes. It could solicit patient enrollment in randomized protocols. It could be a "smart" EHR, and recommend an timely intervention based on published data.
James Moruzzi, MD
The Silber article with data from the Kato Clinic (Tokyo) is historic. It documents the inherent fertility of individual oocytes from natural cycle for a spectrum of maternal ages.
There are a few technical details that may help me in duplicating these results.
- What suction pressure was used on the 21 G Kitazato aspiration needles?
- The clinic monitored cycles with daily ultrasounds, serum estradiol (E2), progesterone (P4) and luteinizing hormone (LH). But it only recommends using follicular size > or = 18 mm, and E2 > or = 250 pg / ml. Were P4 and LH non-predictive of egg maturity?
- Follicular aspiration was scheduled 32 - 35 hours after buserelin inhalation, having met the 18 mm size and E2 criteria. Was the buserelin given that evening? Was urinary LH monitored between the blood draw and administration of buserelin?
- What percentage of these monitored cycles resulted in retrieval of a mature oocyte? What percentage of oocytes were immature or post-mature (atretic)?